Biomedical Engineering Reference
In-Depth Information
142. Tetu, B., and J. Brisson, Prognostic significance of HER-2/neu
oncoprotein expression in node-positive breast cancer. The influence
of the pattern of immunostaining and adjuvant therapy.
Cancer
, 1994.
(9): 2359-2365.
143. Read, L.D.,
73
, Hormonal modulation of HER-2/neu protooncogene
messenger ribonucleic acid and p185 protein expression in human
breast cancer cell lines.
et al.
Cancer Res
, 1990.
50
(13): 3947-3951.
144. Liu, Y.,
, MCF-7 breast cancer cells overexpressing transfected
c-erbB-2 have an
et al.
growth advantage in estrogen-depleted
conditions and reduced estrogen-dependence and tamoxifen-
sensitivity
in vitro
in vivo
.
Breast Cancer Res Treat
, 1995.
34
(2): 97-117.
145. Shou, J.,
, Mechanisms of tamoxifen resistance: increased estrogen
receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
et al.
J
(12): 926-935.
146. Jordan, V.C., and B.W. O'Malley, Selective estrogen-receptor modulators
and antihormonal resistance in breast cancer
Natl Cancer Inst
, 2004.
96
.
J Clin Oncol
, 2007.
(36): 5815-5824.
147. Osborne, C.K.,
25
, Role of the estrogen receptor coactivator AIB1
(SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
et al.
J Natl
Cancer Inst
, 2003.
95
(5): 353-361.
148. Berry, D.A.,
, HER-2/neu and p53 expression versus tamoxifen
resistance in estrogen receptor-positive, node-positive breast cancer.
J Clin Oncol
et al.
, 2000.
18
(20): 3471-3479.
149. Knoop, A.S.,
, Value of epidermal growth factor receptor, HER2,
p53, and steroid receptors in predicting the efficacy of tamoxifen in
high-risk postmenopausal breast cancer patients.
et al.
J Clin Oncol
, 2001.
(14): 3376-3384.
150. Lin, Y.Z., and G.M. Clinton, A soluble protein related to the HER-2 proto-
oncogene product is released from human breast carcinoma cells.
Oncogene
19
, 1991.
6
(4): 639-643.
151. Pupa, S.M.,
, The extracellular domain of the c-erbB-2 oncoprotein
is released from tumor cells by proteolytic cleavage.
et al.
Oncogene
, 1993.
(11): 2917-2923.
152. Zabrecky, J.R.,
8
, The extracellular domain of p185/neu is released
from the surface of human breast carcinoma cells, SK-BR-3.
et al.
J Biol Chem
,
(3): 1716-1720.
153. Codony-Servat, J.,
1991.
266
, Cleavage of the HER2 ectodomain is a
pervanadate-activable process that is inhibited by the tissue inhibitor
of metalloproteases-1 in breast cancer cells.
et al.
Cancer Res
, 1999.
59
(6):
1196-1201.
